Cargando…

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results

This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeed, Anwaar, Park, Robin, Dai, Junqiang, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Saeed, Azhar, Ripp, Jacob, Collins, Zachary, Mulvaney, Kelly, Shugrue, Molly, Firth-Braun, Jeanette, Godwin, Andrew K., Madan, Rashna, Phadnis, Milind, Sun, Weijing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975105/ https://www.ncbi.nlm.nih.gov/pubmed/36702123 http://dx.doi.org/10.1016/j.xcrm.2023.100916

Ejemplares similares

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020)

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
por: Hentzen, Stijn, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study
por: Saeed, Anwaar, et al.
Publicado: (2020)

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience
por: Al-Jumayli, Mohammed, et al.
Publicado: (2019)

First person – Camilla Elinor Korsvig-Nielsen
Publicado: (2019)

The genome sequence of the white admiral, Limenitis camilla (Linnaeus, 1764)
por: Vila, Roger, et al.
Publicado: (2022)

Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review
por: Kasi, Anup, et al.
Publicado: (2020)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

El quinto sol. Una historia diferente de los aztecas, de Camilla Townsend
por: Ladrón de Guevara, Sara
Publicado: (2023)

Snap-jaw morphology is specialized for high-speed power amplification in the Dracula ant, Mystrium camillae
por: Larabee, Fredrick J., et al.
Publicado: (2018)

Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer
por: Karki, Sophiya, et al.
Publicado: (2023)

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
por: Saeed, Anwaar, et al.
Publicado: (2021)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017)

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
por: Ogasawara, Sadahisa, et al.
Publicado: (2022)

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
por: Darragh, Laurel B., et al.
Publicado: (2022)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
por: Richardson, Gary Edward, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
por: Darragh, Laurel B., et al.
Publicado: (2022)

Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?
por: Phadnis, Milind A.
Publicado: (2019)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials
por: Park, Robin, et al.
Publicado: (2021)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Important updates from the AACR virtual meeting: COVID-19 and cancer
por: Ripp, Jacob, et al.
Publicado: (2020)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4kireeq9o2pm7hs4pvcpnceu7k